skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts

Journal Article · · Neuro-Oncology

Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maintained as subcutaneous xenografts (GBMX), and compared GBMX molecular signatures to those observed in GBM clinical specimens derived from the Cancer Genome Atlas (TCGA). The predominant copy number signature in both tumor groups was defined by chromosome-7 gain/chromosome-10 loss, a poor-prognosis genetic signature. We also observed, at frequencies similar to that detected in TCGA GBM tumors, genomic amplification and overexpression of known GBM oncogenes, such as EGFR, MDM2, CDK6, and MYCN, and novel genes, including NUP107, SLC35E3, MMP1, MMP13, and DDX1. The transcriptional signature of GBMX tumors, which was stable over multiple subcutaneous passages, was defined by overexpression of genes involved in M phase, DNA replication, and chromosome organization (MRC) and was highly similar to the poor-prognosis mitosis and cell-cycle module (MCM) in GBM. Assessment of gene expression in TCGA-derived GBMs revealed overexpression of MRC cancer genes AURKB, BIRC5, CCNB1, CCNB2, CDC2, CDK2, and FOXM1, which form a transcriptional network important for G2/M progression and/or checkpoint activation. Our study supports propagation of GBM tumors as subcutaneous xenografts as a useful approach for sustaining key molecular characteristics of patient tumors, and highlights therapeutic opportunities conferred by this GBMX tumor panel for testing targeted therapeutic strategies for GBM treatment.

Research Organization:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
Life Sciences Division
DOE Contract Number:
DE-AC02-05CH11231; CA101777, CA097257, NSO49720
OSTI ID:
983182
Report Number(s):
LBNL-3319E; TRN: US201014%%813
Journal Information:
Neuro-Oncology, Vol. 11, Issue 5
Country of Publication:
United States
Language:
English

Similar Records

LSINCT5 activates Wnt/β-catenin signaling by interacting with NCYM to promote bladder cancer progression
Journal Article · Sun Jul 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:983182

FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1
Journal Article · Fri Jun 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:983182

A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening
Journal Article · Thu Jul 11 00:00:00 EDT 2019 · Cells · OSTI ID:983182